Hybrid cardiac rehabilitation trial (HYCARET): protocol of a randomised, multicentre, non-inferiority trial in South America

被引:9
|
作者
Seron, Pamela [1 ]
Oliveros, Maria J. [1 ]
Marzuca-Nassr, Gabriel N. [2 ]
Lanas, Fernando [1 ]
Morales, Gladys [3 ]
Roman, Claudia [4 ]
Munoz, Sergio R. [5 ]
Saavedra, Nicolas [6 ]
Grace, Sherry L. [7 ,8 ]
机构
[1] Univ La Frontera, CIGES, Internal Med Dept, Temuco, Chile
[2] Univ La Frontera, Internal Med Dept, Temuco, Chile
[3] Univ La Frontera, EPICYN, Publ Hlth Dept, Temuco, Chile
[4] Pontificia Univ Catolica Chile, Fac Med, Santiago, Chile
[5] Univ La Frontera, CIGES, Publ Heath Dept, Temuco, Chile
[6] Univ La Frontera, Basic Sci Dept, Temuco, Chile
[7] York Univ, Fac Hlth, Toronto, ON, Canada
[8] Univ Toronto, Univ Hlth Network, KITE & Peter Munk Cardiac Ctr, Toronto, ON, Canada
来源
BMJ OPEN | 2019年 / 9卷 / 10期
关键词
MYOCARDIAL-INFARCTION; PERFORMANCE-MEASURES; PHYSICAL-ACTIVITY; DELIVERY MODEL; PREVENTION; STATEMENT; ASSOCIATION; RECOMMENDATIONS; QUESTIONNAIRE; COUNCIL;
D O I
10.1136/bmjopen-2019-031213
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Cardiac rehabilitation (CR) programmes are well established, and their effectiveness and cost-effectiveness are proven. In spite of this, CR remains underused, especially in lower-resource settings such as Latin America. There is an urgent need to create more accessible CR delivery models to reach all patients in need. This trial aims to evaluate if the prevention of recurrent cardiovascular events is not inferior in a hybrid CR programme compared with a standard programme. Method and analysis A non-inferiority, pragmatic, multicentre, parallel (1:1), prospective, randomised and open with blinded endpoint assessment clinical trial will be conducted. 308 patients with coronary artery disease will be recruited consecutively. Participants will be randomised to hybrid or standard rehabilitation programme. The hybrid CR programme includes 10 supervised exercise sessions and individualised lifestyle counselling by a physiotherapist, with a transition after 4-6 weeks to unsupervised delivery via text messages and phone calls. The standard CR consists of 18-22 supervised exercise sessions, as well as group education sessions about lifestyle. Intervention in both groups is between 8 and 12 weeks. The primary outcome is a composite of cardiovascular mortality and hospitalisations due to cardiovascular causes. Secondary outcomes are health-related quality of life, exercise capacity, muscle strength, heart-healthy behaviour, return-to-work, cardiovascular risk factor, adherence, and exercise-related adverse events. The outcomes will be measured at the end of intervention, at 6 months and at 12 months follow-up from recruitment. The primary outcome will be tracked through the end of the trial. Per-protocol and intention-to-treat analysis will be undertaken. Cox regression model will be used to compare primary outcome among study groups. Ethics and dissemination Ethics committees at the sponsor institution and each centre where participants will be recruited approved the study protocol and the Informed Consent. Research findings will be published in peer-reviewed journals; additionally, results will be disseminated among region stakeholders.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Chapter 6 Non-inferiority Trial
    Peter Pang
    实用休克杂志(中英文), 2019, 3 (04) : 254 - 256
  • [42] The perioperative administration of dexamethasone and infection (PADDI) trial protocol: rationale and design of a pragmatic multicentre non-inferiority study
    Corcoran, Tomas B.
    Myles, Paul S.
    Forbes, Andrew B.
    O'Loughlin, Ed
    Leslie, Kate
    Story, David
    Short, Timothy G.
    Chan, Matthew T. V.
    Coutts, Pauline
    Sidhu, Jaspreet
    Cheng, Allen C.
    Bach, Leon A.
    Ho, Kwok M.
    BMJ OPEN, 2019, 9 (09):
  • [43] SUGAR-DIP trial: oral medication strategy versus insulin for diabetes in pregnancy, study protocol for a multicentre, open-label, non-inferiority, randomised controlled trial
    de Wit, Leon
    Rademaker, Doortje
    Voormolen, Daphne N.
    Akerboom, Bettina M. C.
    Kiewiet-Kemper, Rosalie M.
    Soeters, Maarten R.
    Verwij-Didden, Marion A. L.
    Assouiki, Fahima
    Schippers, Daniela H.
    Vermeulen, Mechteld A. R.
    Kuppens, Simone M. I.
    Oosterwerff, Mirjam M.
    Zwart, Joost J.
    Diekman, Mattheus J. M.
    Vogelvang, Tatjana E.
    Gallas, P. Rob J.
    Galjaard, Sander
    Visser, Willy
    Horree, Nicole
    Klooker, Tamira K.
    Laan, Rosemarie
    Heijligenberg, Rik
    Huisjes, Anjoke J. M.
    van Bemmel, Thomas
    van Meir, Claudia A.
    van den Beld, Annewieke W.
    Hermes, Wietske
    Vidarsdottir, Solrun
    Veldhuis-Vlug, Anneke G.
    Dullemond, Remke C.
    Jansen, Henrique J.
    Sueters, Marieke
    de Koning, Eelco J. P.
    van Laar, Judith O. E. H.
    Wouters-van Poppel, Pleun
    Sanson-van Praag, Marina E.
    van den Akker, Eline S.
    Brouwer, Catherine B.
    Hermsen, Brenda B.
    Potter van Loon, Bert Jan
    van der Heijden, Olivier W. H.
    de Galan, Bastiaan E.
    van Leeuwen, Marsha
    Wijbenga, Johanna A. M.
    de Boer, Karin
    van Bon, Arianne C.
    van der Made, Flip W.
    Eskes, Silvia A.
    Zandstra, Mirjam
    van Houtum, William H.
    BMJ OPEN, 2019, 9 (08):
  • [44] Early treatment versus expectative management of patent ductus arteriosus in preterm infants: a multicentre, randomised, non-inferiority trial in Europe (BeNeDuctus trial)
    Tim Hundscheid
    Wes Onland
    Bart van Overmeire
    Peter Dijk
    Anton H. L. C. van Kaam
    Koen P. Dijkman
    Elisabeth M. W. Kooi
    Eduardo Villamor
    André A. Kroon
    Remco Visser
    Daniel C. Vijlbrief
    Susanne M. de Tollenaer
    Filip Cools
    David van Laere
    Anne-Britt Johansson
    Catheline Hocq
    Alexandra Zecic
    Eddy Adang
    Rogier Donders
    Willem de Vries
    Arno F. J. van Heijst
    Willem P. de Boode
    BMC Pediatrics, 18
  • [45] Early treatment versus expectative management of patent ductus arteriosus in preterm infants: a multicentre, randomised, non-inferiority trial in Europe (BeNeDuctus trial)
    Hundscheid, Tim
    Onland, Wes
    van Overmeire, Bart
    Dijk, Peter
    van Kaam, Anton H. L. C.
    Dijkman, Koen P.
    Kooi, Elisabeth M. W.
    Villamor, Eduardo
    Kroon, Andre A.
    Visser, Remco
    Vijlbrief, Daniel C.
    de Tollenaer, Susanne M.
    Cools, Filip
    van Laere, David
    Johansson, Anne-Britt
    Hocq, Catheline
    Zecic, Alexandra
    Adang, Eddy
    Donders, Rogier
    de Vries, Willem
    van Heijst, Arno F. J.
    de Boode, Willem P.
    BMC PEDIATRICS, 2018, 18
  • [46] TECHNOLOGICAL ASSISTED REHABILITATION FOLLOWING TOTAL KNEE JOINT REPLACEMENT. A RANDOMISED CONTROLLED NON-INFERIORITY TRIAL
    Andersen, H. H.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1823 - 1824
  • [47] Restrictive transfusion strategy for critically injured patients (RESTRIC) trial: a study protocol for a cluster-randomised, crossover non-inferiority trial
    Hayakawa, Mineji
    Tagami, Takashi
    IIjima, Hiroaki
    Kudo, Daisuke
    Sekine, Kazuhiko
    Ogura, Takayuki
    Yumoto, Tetsuya
    Kondo, Yutaka
    Endo, Akira
    Ito, Kaori
    Matsumura, Yosuke
    Kushimoto, Shigeki
    BMJ OPEN, 2020, 10 (09):
  • [48] Efficacy of MRI in primary care for patients with knee complaints due to trauma: Protocol of a randomised controlled non-inferiority trial (TACKLE trial)
    Swart N.M.
    Van Oudenaarde K.
    Algra P.R.
    Bindels P.J.
    Van Den Hout W.B.
    Koes B.W.
    Nelissen R.G.
    Verhaar J.A.
    Bloem H.J.
    Bierma-Zeinstra S.M.
    Reijnierse M.
    Luijsterburg P.A.
    BMC Musculoskeletal Disorders, 15 (1)
  • [49] Optical coherence tomography versus punch biopsy for diagnosis of basal cell carcinoma: a multicentre, randomised, non-inferiority trial
    Adan, Fieke
    Nelemans, Patty J.
    Essers, Brigitte A. B.
    Brinkhuizen, Tjinta
    Dodemont, Sharon R. P.
    Kessels, Janneke P. H. M.
    Quaedvlieg, Patricia J. F.
    Dermont, Gert-Jan
    Winnepenninckx, Veronique J. L.
    Hamid, Myrurgia Abdul
    Kelleners-Smeets, Nicole W. J.
    Mosterd, Klara
    LANCET ONCOLOGY, 2022, 23 (08): : 1087 - 1096
  • [50] RANDOMISED, OPEN LABEL MULTICENTRE, NON-INFERIORITY CLINICAL TRIAL FOR NEW TREATMODALITIES FOR CUTANEOUS LEISHMANIASIS CAUSED BY LEISHMANIA TROPICA
    Kamink, S.
    Lenglet, A.
    Pylypenko, T.
    Jensen, T.
    Ashraf, S.
    Kamau, C.
    Fernhout, J.
    den Boer, M.
    Ritmeijer, K.
    TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2019, 113 : S157 - S157